Certolizumab pegol: Difference between revisions
No edit summary |
m Protected "Certolizumab pegol": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
(No difference)
| |
Revision as of 20:19, 27 September 2011
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Certolizumab pegol (CDP870) is a PEGylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody.
It is the subject of phase III clinical trials in both Crohn's disease[1] and rheumatoid arthritis. [2]
Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol vs placebo in moderate to severe active Crohn's disease.
In addition, data from both trials suggest it is well-tolerated. As yet its efficacy has not been directly compared to other anti-TNF-alpha agents.
References
- ↑ Sandborn WJ, Feagan BG, Stoinov S; et al. (2007). "Certolizumab pegol for the treatment of Crohn's disease". N. Engl. J. Med. 357 (3): 228–38. doi:10.1056/NEJMoa067594. PMID 17634458.
- ↑ Kaushik VV, Moots RJ (2005). "CDP-870 (certolizumab) in rheumatoid arthritis". Expert opinion on biological therapy. 5 (4): 601–6. doi:10.1517/14712598.5.4.601. PMID 15934837.
External links
- certolizumab+pegol at the US National Library of Medicine Medical Subject Headings (MeSH)